Login
Cart
Support
Search
Search
Search
Doris Pröbstl
Appearances
View Grid
FIRST IN HUMAN TRIAL OF IMU-856, AN ORALLY AVAILABLE EPIGENETIC MODULATOR OF BARRIER REGENERATION FOR THE TREATMENT OF CELIAC DISEASE
Date
May 20, 2024
Objective: IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6, a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium…
Presenter
Franziska Buriánek
Speakers
Doris Pröbstl
Evelyn Peelen
Juliano Fonseca
Amelie Schreieck
Martina Wirth
Inge Kehler
Daniel Vitt
Hella Kohlhof
Andreas Muehler